Maxion Therapeutics has just closed a record-breaking £58 million Series A funding round, marking the largest private biotech investment in Europe since early 2024. This impressive round was led by General Catalyst, while new backers such as British Patient Capital, Solasta Ventures, and Eli Lilly joined seasoned supporters like LifeArc Ventures, Monograph Capital, and BGF. Alongside this investment, the company also received a £2 million Innovate UK grant to further its ion channel antibody research for autoimmune diseases.
Bridging the Treatment Gap with the KnotBody Platform
Although antibodies are known for their specificity and safety, no current antibody drugs effectively target ion channels. This gap is especially critical when treating diseases linked to ion channels and G-protein-coupled receptors (GPCRs). Maxion Therapeutics is tackling this challenge head-on with its innovative KnotBody platform. By merging antibodies with small, cysteine-rich miniproteins called knottins, Maxion has created a new class of therapeutics that promises potent and selective treatments for previously “untargetable” proteins.
A Game-Changer in Biologic Drug Discovery
Founded in Cambridge in 2020, Maxion Therapeutics builds on groundbreaking research from Dr. John McCafferty and Dr. Aneesh Karatt-Vellatt. Dr. McCafferty, a pioneer behind antibody phage display technology and a Nobel laureate for his work that led to the development of Humira, joined forces with Dr. Karatt-Vellatt—another key figure in antibody innovation—to address the limitations of traditional therapies. Together, they are now redefining how biologic drugs target ion channels and GPCRs.
Their KnotBody platform leverages the natural properties of knottins, which are effective ion channel modulators, and combines them with the drug-like features of antibodies. This blend results in therapeutics that are not only more potent but also offer enhanced selectivity and durability compared to conventional antibody treatments. By addressing a major medical need, Maxion is positioning itself as a trailblazer in the field.
Driving Innovation in Challenging Therapeutic Areas
Ion channels and GPCRs are key drivers in many diseases, including autoimmune conditions, chronic pain, and cardiovascular disorders. However, despite their importance, current treatments are limited. Small-molecule drugs often lack the selectivity needed to avoid side effects, and traditional antibody therapies have struggled to engage these targets effectively.
Maxion’s KnotBody platform changes the game. By utilizing advanced phage and mammalian display technologies, the company has developed molecules that merge the strengths of knottins and antibodies. This innovative approach not only enhances the potency and selectivity of the treatments but also improves their long-term effectiveness. The result is a pipeline of potential therapeutics that could transform treatment for patients facing debilitating diseases.
Pioneering Programs and Future Prospects
Maxion is already making strides with its lead candidate, MAX001, which is undergoing preclinical development. This program targets inflammatory conditions such as atopic dermatitis and inflammatory bowel disease. In parallel, the company is exploring early-stage KnotBody molecules aimed at managing chronic pain and cardiovascular disease.
The excitement around Maxion’s progress is palpable. Industry experts believe that KnotBody technology holds the key to unlocking therapies for conditions that have long been deemed difficult or even impossible to treat with existing methods. With a robust investor syndicate and a team driven by passion and expertise, Maxion is set to transform the biologics discovery process.
Voices of Confidence from Industry Leaders
Arndt Schottelius, MD PhD, CEO of Maxion Therapeutics, commented, “KnotBodies represent a potential breakthrough biologic drug modality. We are confident that our platform will deliver transformational treatments for ion channel and GPCR-driven diseases. The strong support from our international investors underscores the promise of our approach.”
Emma Johnson, Senior Investment Manager at British Patient Capital, added, “Backing Maxion at this pivotal moment reflects our commitment to innovative science. Their KnotBody platform has the potential to open up entirely new therapeutic avenues and ultimately benefit patients worldwide.”
Elena Viboch, Managing Director at General Catalyst, noted, “Maxion is radically shifting the way we approach biologics discovery. Their differentiated KnotBody platform is poised to tackle some of the most challenging drug targets, promising significant advancements in patient care.”
Transforming Global Therapeutics
Maxion Therapeutics’ breakthrough is more than just another funding milestone—it’s a step forward in addressing some of the most stubborn challenges in modern medicine. With a clear focus on improving the selectivity and efficacy of treatments for ion channel and GPCR-driven diseases, the company’s KnotBody platform is set to redefine the future of biologic drugs.
As the biotech industry continues to evolve, Maxion’s progress will likely pave the way for more precise and effective therapies. This fresh approach not only fills a significant gap in the current treatment landscape but also highlights the critical role of innovation in overcoming longstanding medical challenge.
With its robust funding and a groundbreaking platform, Maxion Therapeutics is well-positioned to expand its research and clinical programs. The next steps involve pushing KnotBody molecules through rigorous proof-of-concept studies and eventually into clinical trials. If successful, these novel therapeutics could provide much-needed relief for patients suffering from a range of severe conditions.
The implications of this advancement extend beyond just one company. Success here could open the door for further innovations in biologics, inspiring other companies to explore new ways of targeting elusive proteins. Ultimately, this could lead to a new era in drug development—one that offers safer, more effective, and longer-lasting treatments.
For more funding news, click here.
